Amgen Inc. and Johnson & Johnson won’t face new reimbursement limits for their anemia medicines, Blooberg reported today.
“The Centers for Medicare and Medicaid Services proposed in March to maintain current standards for using Amgen’s Aranesp and Epogen and J&J’s Procrit, leaving coverage determination to regional Medicare contractors that process reimbursement claims. The agency made the proposal final today,” Bloomberg reported.
To read more, click here.
